Literature DB >> 23150372

Assessment of mitochondrial damage in retinal cells and tissues using quantitative polymerase chain reaction for mitochondrial DNA damage and extracellular flux assay for mitochondrial respiration activity.

Stuart G Jarrett1, Bärbel Rohrer, Nathan R Perron, Craig Beeson, Michael E Boulton.   

Abstract

Mitochondrial dysfunction and genomic instability are associated with a number of retinal pathologies including age-related macular degeneration, diabetic retinopathy, and glaucoma. Consequences of mitochondrial dysfunction within cells include elevation of the rate of ROS production due to damage of electron transport chain proteins, mitochondrial DNA (mtDNA) damage, and loss of metabolic capacity. Here we introduce the quantitative polymerase chain reaction assay (QPCR) and extracellular flux assay (XF) as powerful techniques to study mitochondrial behavior. The QPCR technique is a gene-specific assay developed to analyze the DNA damage repair response in mitochondrial and nuclear genomes. QPCR has proved particularly valuable for the measurement of oxidative-induced mtDNA damage and kinetics of mtDNA repair. To assess the functional consequence of mitochondrial oxidative damage, real-time changes in cellular bioenergetics of cell monolayers can be measured with a Seahorse Biosciences XF24 analyzer. The advantages and limitations of these procedures will be discussed and detailed methodologies provided with particular emphasis on retinal oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23150372     DOI: 10.1007/978-1-62703-080-9_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  In vitro studies in VCP-associated multisystem proteinopathy suggest altered mitochondrial bioenergetics.

Authors:  Angèle Nalbandian; Katrina J Llewellyn; Arianna Gomez; Naomi Walker; Hailing Su; Andrew Dunnigan; Marilyn Chwa; Jouni Vesa; M C Kenney; Virginia E Kimonis
Journal:  Mitochondrion       Date:  2015-02-25       Impact factor: 4.160

2.  Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.

Authors:  Lalit P Singh
Journal:  J Clin Exp Ophthalmol       Date:  2013-08-05

3.  Age-related accumulation of phosphorylated mitofusin 2 protein in retinal ganglion cells correlates with glaucoma progression.

Authors:  Mary P Nivison; Nolan G Ericson; Virginia M Green; Jason H Bielas; Jean S Campbell; Philip J Horner
Journal:  Exp Neurol       Date:  2017-07-03       Impact factor: 5.330

Review 4.  Patient derived stem cells for discovery and validation of novel pathogenic variants in inherited retinal disease.

Authors:  Nathaniel K Mullin; Andrew P Voigt; Jessica A Cooke; Laura R Bohrer; Erin R Burnight; Edwin M Stone; Robert F Mullins; Budd A Tucker
Journal:  Prog Retin Eye Res       Date:  2020-10-29       Impact factor: 21.198

5.  Repressed SIRT1/PGC-1α pathway and mitochondrial disintegration in iPSC-derived RPE disease model of age-related macular degeneration.

Authors:  Nady Golestaneh; Yi Chu; Shuk Kei Cheng; Hong Cao; Eugenia Poliakov; Daniel M Berinstein
Journal:  J Transl Med       Date:  2016-12-20       Impact factor: 5.531

Review 6.  Cellular Senescence in Age-Related Macular Degeneration: Can Autophagy and DNA Damage Response Play a Role?

Authors:  Janusz Blasiak; Malgorzata Piechota; Elzbieta Pawlowska; Magdalena Szatkowska; Ewa Sikora; Kai Kaarniranta
Journal:  Oxid Med Cell Longev       Date:  2017-11-01       Impact factor: 6.543

7.  Pgc-1α repression and high-fat diet induce age-related macular degeneration-like phenotypes in mice.

Authors:  Meng Zhang; Yi Chu; Joseph Mowery; Brandon Konkel; Susana Galli; Alexander C Theos; Nady Golestaneh
Journal:  Dis Model Mech       Date:  2018-08-16       Impact factor: 5.758

8.  Dysregulated metabolic pathways in age-related macular degeneration.

Authors:  Meng Zhang; Nisi Jiang; Yi Chu; Olga Postnikova; Rency Varghese; Anelia Horvath; Amrita K Cheema; Nady Golestaneh
Journal:  Sci Rep       Date:  2020-02-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.